blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4171632

EP4171632 - METHODS OF TREATING INFLAMMATORY BOWEL DISEASE WITH TL1A ANTIBODIES [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  31.03.2023
Database last updated on 18.01.2025
FormerThe international publication has been made
Status updated on  31.12.2021
Formerunknown
Status updated on  14.07.2021
Most recent event   Tooltip02.07.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192 / US
[2023/18]
Inventor(s)01 / BANIECKI, Mary Lynn
Cambridge, Massachusetts 02139 / US
02 / HASSAN-ZAHRAEE, Mina
Cambridge, Massachusetts 02139 / US
03 / HUNG, Kenneth Eugene
Cambridge, Massachusetts 02139 / US
04 / LI, Gang
Collegeville, Pennsylvania 19426 / US
05 / XI, Li
Cambridge, Massachusetts 02139 / US
06 / YE, Zhan
Cambridge, Massachusetts 02139 / US
 [2023/18]
Representative(s)Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
[2023/18]
Application number, filing date21736707.723.06.2021
[2023/18]
WO2021IB55546
Priority number, dateUS202063044390P26.06.2020         Original published format: US 202063044390 P
[2023/18]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2021260577
Date:30.12.2021
Language:EN
[2021/52]
Type: A2 Application without search report 
No.:EP4171632
Date:03.05.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 30.12.2021 takes the place of the publication of the European patent application.
[2023/18]
Search report(s)International search report - published on:EP28.04.2022
ClassificationIPC:A61K39/395, A61P43/00, A61P37/06, A61P29/00, A61K39/00
[2023/18]
CPC:
A61P29/00 (EP,KR); C07K16/2875 (EP,KR,US); A61P1/04 (KR);
A61P1/12 (US); A61P37/06 (EP); A61P43/00 (EP);
C12Q1/6883 (KR); A61K2039/505 (EP,KR); A61K2039/545 (EP,KR);
C07K2317/90 (KR); C12Q2600/106 (KR) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/18]
TitleGerman:VERFAHREN ZUR BEHANDLUNG VON ENTZÜNDLICHER DARMERKRANKUNG MIT TL1A-ANTIKÖRPERN[2023/18]
English:METHODS OF TREATING INFLAMMATORY BOWEL DISEASE WITH TL1A ANTIBODIES[2023/18]
French:MÉTHODES DE TRAITEMENT D'UNE AFFECTION ABDOMINALE INFLAMMATOIRE À L'AIDE D'ANTICORPS TL1A[2023/18]
Entry into regional phase26.01.2023National basic fee paid 
26.01.2023Designation fee(s) paid 
26.01.2023Examination fee paid 
Examination procedure26.01.2023Examination requested  [2023/18]
26.01.2023Date on which the examining division has become responsible
01.08.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
30.06.2023Renewal fee patent year 03
01.07.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XI]WO2015035261  (CEDARS SINAI MEDICAL CENTER [US]) [X] 7,8,10 * abstract, p. 1 line 29 - p. 4 line 14, p. 10 line 17 - p. 12 line 17, examples 1-6 and claims * [I] 1-6,9,11-22;
 [I]US2015132311  (ARCH ROBERT [US], et al) [I] 1-22 * abstract, [0009]-[0068], [0512]-[0521], [0884]-[0896], examples 1-24 and claims *;
 [A]WO2017201461  (CEDARS SINAI MEDICAL CENTER [US]) [A] 1-22 * the whole document *;
 [I]WO2018081074  (CEDARS SINAI MEDICAL CENTER [US]) [I] 1-22 * abstract, [0004]-[0013], examples 1-10 and claims *;
 [I]WO2019209995  (PREC IBD INC [US]) [I] 1-22 * abstract, [0005]-[0015], examples 1-14 and claims *;
 [A]  - HABERMAN YAEL ET AL, "Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response", NATURE COMMUNICATIONS, vol. 10, no. 1, doi:10.1038/s41467-018-07841-3, (20191201), pages 1 - 13, URL: https://www.nature.com/articles/s41467-018-07841-3.pdf, XP055889426 [A] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1038/s41467-018-07841-3
 [A]  - YANG XIAONAN ET AL, "High-Throughput Transcriptome Profiling in Drug and Biomarker Discovery", FRONTIERS IN GENETICS, (20200205), vol. 11, doi:10.3389/fgene.2020.00019, XP055889408 [A] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.3389/fgene.2020.00019
 [A]  - THIÉBAUT R ET AL, "TNFSF15 Polymorphisms Are Associated With Susceptibility to Inflammatory Bowel Disease in a New European Cohort", AMERICAN JOURNAL OF GASTROENTEROLOGY, US, vol. 104, no. 2, doi:10.1038/ajg.2008.36, ISSN 0002-9270, (20090201), pages 384 - 391, URL: http://dx.doi.org/10.1038/ajg.2008.36, XP055889446 [A] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1038/ajg.2008.36
 [A]  - YOANA PICORNELL ET AL, "TNFSF15 is an ethnic-specific IBD gene :", HHS PUBLIC ACCESS AUTHOR MANUSCRIPT, US, (20071101), vol. 13, no. 11, doi:10.1002/ibd.20223, ISSN 1078-0998, pages 1333 - 1338, XP055444532 [A] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1002/ibd.20223
 [A]  - DAVID Q SHIH ET AL, "Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells", EUROPEAN JOURNAL OF IMMUNOLOGY, WILEY-VCH, HOBOKEN, USA, (20091016), vol. 39, no. 11, doi:10.1002/EJI.200839087, ISSN 0014-2980, pages 3239 - 3250, XP071224335 [A] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1002/eji.200839087
 [A]  - ADEN KONRAD ET AL, "The Gut Microbiome in Inflammatory Bowel Diseases: Diagnostic and Therapeutic Implications", VISCERAL MEDICINE, vol. 35, no. 6, doi:10.1159/000504148, ISSN 2297-4725, (20190101), pages 332 - 337, URL: https://www.karger.com/Article/Pdf/504148, XP055889146 [A] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1159/000504148
 [A]  - MALHAM MIKKEL ET AL, "The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, UK, vol. 54, no. 8, doi:10.1080/00365521.2019.1644368, ISSN 0036-5521, (20190803), pages 969 - 975, URL: http://dx.doi.org/10.1080/00365521.2019.1644368, XP055889144 [A] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1080/00365521.2019.1644368
 [A]  - SRIVASTAVA ANKITA ET AL, "Gut biofilm forming bacteria in inflammatory bowel disease", MICROBIAL PATHOGENESIS, ACADEMIC PRESS LIMITED, NEW YORK, NY, US, (20170920), vol. 112, doi:10.1016/J.MICPATH.2017.09.041, ISSN 0882-4010, pages 5 - 14, XP085251760 [A] 1-22

DOI:   http://dx.doi.org/10.1016/j.micpath.2017.09.041
 [A]  - SCOTT E. PLEVY ET AL, "Future Therapeutic Approaches for Inflammatory Bowel Diseases", GASTROENTEROLOGY, (20110501), vol. 140, no. 6, doi:10.1053/j.gastro.2011.02.014, ISSN 0016-5085, pages 1838 - 1846, XP055013564 [A] 1-22 * the whole document *

DOI:   http://dx.doi.org/10.1053/j.gastro.2011.02.014
by applicantUS3773919
 US4485045
 US4544545
 US4816567
 US5013556
 US5047335
 US5278299
 US5510261
 US7314622
    - RUBIN et al., Am J Gastroenterol, (20190000), vol. 114, pages 384 - 413
    - LICHTENSTEIN et al., Am J Gastroenterol, (20180000), vol. 113, pages 481 - 517
    - WALLACE et al., World J Gastroenterol, (20140000), vol. 20, pages 6 - 21
    - HARITUNIANS et al., Inflammatory bowel diseases, (20100000), vol. 16, pages 1830 - 1840
    - BAMIAS et al., Clin Immunol, (20100000), vol. 137, pages 242 - 249
    - MIGONE et al., Immunity, (20020000), vol. 16, pages 479 - 492
    - TAKEDATSU et al., Gastroenterology, (20080000), vol. 135, pages 552 - 567
    - MEYLAN et al., Mucosal Immunity, (20110000), vol. 4, pages 172 - 185
    - MEYLAN et al., Immunity, (20080000), vol. 29, pages 79 - 89
    - DIGNASS et al., J Crohn's Colitis., (20120000), vol. 6, no. 10, pages 965 - 90
    - RUTTER et al., Gastroenterology, (20040000), vol. 126, no. 2, pages 451 - 9
    - DE LANGE et al., Nat Genet, (20170000), vol. 49, no. 2, pages 256 - 610
    - SIAKAVELLAS et al., Inflamm. Bowel Dis., (20150000), vol. 21, no. 10, pages 2441 - 52
    - YANG et al., J Crohns Colitis, (20140000), vol. 8, no. 10, pages 1315 - 26
    - TUNG et al., J Gasteroenterl Hepatol, (20140000), vol. 29, no. 4, pages 273 - 9
    - BAMIAS et al., Curr Opinion Gasteroenterol., (20130000), vol. 29, no. 6, pages 597 - 602
    - PREHN et al., Clin Immunol, (20040000), vol. 112, no. 1, pages 66 - 77
    - CASTELLANOS et al., Mucosal Immunol, (20190000), vol. 11, no. 5, pages 1466 - 1476
    - HEDLABRAHAM, PNAS, (20140000), vol. 111, no. 37, pages 13451 - 13456
    - CLARKE et al., MAbs, (20020000), vol. 10, pages 664 - 677
    - MEYLAN et al., Mucosal Immunol, (20140000), vol. 7, no. 4, pages 1492 - 1503
    - COMMINELLI et al., Curr Opin Gastroenterol, (20130000), vol. 29, pages 597 - 602
    - CASTELLANOSLONGMAN, J Clin Invest, (20190000), vol. 129, pages 2640 - 2650
    - CITE RICHARD et al., J Immunol, (20150000), vol. 194, pages 3567 - 82
    - MEYLAN et al., Mucosal Immunol, (20110000), vol. 4, no. 2, pages 172 - 185
    - SHIH et al., PLoS One, (20110000), vol. 6, no. 1, page e16090
    - LI et al., Pathol Res Pract, (20180000), vol. 214, pages 217 - 227
    - GEVERS et al., Cell Host Microbe, (20140000), vol. 15, pages 382 - 392
    - SAID et al., Int J Inflam, (20130000), vol. 2013, page 581409
    - ATARASHI, Science, (20170000), vol. 358, pages 359 - 365
    - DOHERTY et al., mBio, (20180000), pages e02120 - 17
    - CHOTHIA et al., Nature, (19890000), vol. 342, pages 877 - 83
    - CHOTHIALESK, J Mol Biol, (19870000), vol. 196, no. 4, pages 901 - 917
    - CAPEL et al., Immunomethods, (19940000), vol. 4, pages 1993 - 1998
    - RAVETCHKINET, Ann. Rev. Immunol., (19910000), vol. 9, pages 457 - 92
    - SAMUDRALA et al., "Ab Initio Protein Structure Prediction Using a Combined Hierarchical Approach", PROTEINS, Structure, Function and Genetics, (19990000), vol. 3, pages 194 - 198, XP001146416
    - JEFFERISLUND, Chem. Immunol., (19970000), vol. 65, pages 111 - 128
    - JOHNSONWU, Nucleic Acids Res., (20000000), vol. 28, pages 214 - 8
    - DE HAAS et al., J. Lab. Clin. Med., (19950000), vol. 126, pages 330 - 41
    - CHOTHIA et al., J. Mol. Biol., (19860000), vol. 196, pages 901 - 17
    - MARTIN et al., Proc Natl Acad Sci (USA, (19890000), vol. 86, pages 9268 - 9272
    - MACCALLUM et al., J. Mol. Biol., (19960000), vol. 5, pages 732 - 45
    - MAKABE et al., Journal of Biological Chemistry, (20080000), vol. 283, pages 1156 - 1166
    - KOHLER, B.MILSTEIN, C., Nature, (19750000), vol. 256, pages 495 - 497
    - MCCAFFERTY et al., Nature, (19900000), vol. 348, pages 552 - 554
    - GUYER et al., J. Immunol., (19760000), vol. 117, page 587
    - KIM et al., J. Immunol., (19940000), vol. 24, page 249
    - ARANZAZU, J-E., Journal of Crohn's and Colitis, (20170000), vol. 11, no. 3, pages 305 - 313
    - WITTWEHOWARD, Biochem., (19900000), vol. 29, pages 4175 - 4180
    - BUCK, D. W. et al., In Vitro, (19820000), vol. 18, pages 377 - 381
    - TILLER et al., J. Immunol. Methods, (20080000), vol. 329, page 112
    - WRIGHTMORRISON, TibTECH, (19970000), vol. 15, pages 26 - 32
    - BOYD et al., Mol. Immunol., (19960000), vol. 32, pages 1311 - 1318
    - WYSSWAGNER, Current Opin. Biotech., (19960000), vol. 7, pages 409 - 416
    - UMANA et al., Nature Biotech., (19990000), vol. 17, pages 176 - 180
    - HSE et al., J. Biol. Chem., (19970000), vol. 272, pages 9062 - 9070
    - EPSTEIN et al., Proc. Natl. Acad. Sci. USA, (19850000), vol. 82, page 3688
    - HWANG et al., Proc. Natl Acad. Sci. USA, (19800000), vol. 77, page 4030
    - SIMON R., Control Clin Trials, (19890000), vol. 10, pages 1 - 10
    - SCHROEDER et al., N Engl J Med, (19870000), vol. 317, pages 1625 - 1629
    - SANDS BEPEYRIN-BIROULET LLOFTUS EV, JR. et al., "Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis", N Engl J Med, (20190000), vol. 381, pages 1215 - 1226
    - BENJAMINIHOCHBERG, Stat Med, (19900700), vol. 9, no. 7, pages 811 - 8
    - LAKE et al., Hum Hered, (20030000), vol. 55, no. 1, pages 56 - 65
    - BISCHL et al., Journal of Machine Learning Research, vol. 17, no. 170, pages 1 - 5
    - J Gastroenterol., (20180900), vol. 53, no. 9, pages 1048 - 1064
    - THIEBAUT et al., Am J Gastroenterol., (20090000), vol. 104, no. 2, pages 384 - 91
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.